CLVS News and Press, Clovis Oncology Inc. From 09/13/22

Clovis Oncology ( NASDAQ: CLVS ) said it submitted applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for approval of Rubraca (rucaparib) as a first-line maintenance therapy for women with advanced ovarian cancer reg...

Cancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. Investors pushed the company's share price up by more than 30% on the day, thanks to highly encouraging clinical trial results for a new indication of its oncology drug Rubraca. On Sunday, Clovis r...

If you’re looking for penny stocks to buy and hold, this might be a bit of a tough market for you. But if you’re trading penny stocks or looking for stocks to buy in the short term, recent volatility spikes have become a day trader’s dream. This week is setting ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Tattoboo / Shutterstock Adobe (NASDAQ: ADBE ) stock is sliding lower on Monday after the software company was hit with a downgrade from Mizuho analyst Gregg Moskowitz. The Mizuho analyst dropped the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is rising higher on Monday following the release of results from a Phase 3 clinical trial . That trail covers Rubraca as a monotherap...

Clovis Oncology ( NASDAQ: CLVS ) said Rubraca as initial maintenance therapy improved progression-free survival (PFS), compared to placebo across disease risk subgroups in patients with ovarian cancer. The company presented data from a subgroup analysis ...

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential of Rubraca as a first-line maintenance treatment option in a broad population of...

Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro ...

Gainers: OraSure Technologies ( OSUR ) +28% . BioAtla ( BCAB ) +24% . Catalyst Pharmaceuticals ( CPRX ) +16% . Clovis Oncology ( CLVS ) +13% . Quanterix ( QTRX ) +13% . Losers: Singular Genomics Systems ( OMIC ...

Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. As of 12:47 p.m. ET on Monday, the company's stock price was down by a noteworthy 12.8% on relatively modest volume. After this latest dip, Clovis' stock is down by over 46% for the yea...